S
CRNX

SignatureFD’s Crinetics Pharmaceuticals CRNX Stock Holding History

SignatureFD’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Sell
387
-123
-24% -$4.57K ﹤0.01% 2494
2026
Q1 		$18.5K Sell
510
-4
-0.8% -$179 ﹤0.01% 2231
2025
Q4 		$23.9K Buy
514
+126
+32% +$5.61K ﹤0.01% 2039
2025
Q3 		$16.2K Buy
388
+91
+31% +$2.91K ﹤0.01% 2212
2025
Q2 		$8.54K Sell
297
-65
-18% -$2.01K ﹤0.01% 2410
2025
Q1 		$12.1K Sell
362
-117
-24% -$4.37K ﹤0.01% 2281
2024
Q4 		$24.5K Hold
479
– – ﹤0.01% 1962
2024
Q3 		$24.5K Hold
479
– – ﹤0.01% 1940
2024
Q2 		$21.5K Buy
479
+174
+57% +$8.04K ﹤0.01% 1936
2024
Q1 		$14.3K Buy
305
+4
+1% +$157 ﹤0.01% 2169
2023
Q4 		$10.7K Sell
301
-200
-40% -$6.13K ﹤0.01% 2232
2023
Q3 		$14.9K Buy
501
+218
+77% +$4.49K ﹤0.01% 2008
2023
Q2 		$5.1K Sell
283
-15
-5% -$299 ﹤0.01% 2512
2023
Q1 		$4.79K Buy
298
+7
+2% +$130 ﹤0.01% 2522
2022
Q4 		$5.33K Sell
291
-106
-27% -$1.87K ﹤0.01% 2451
2022
Q3 		$8K Buy
397
+114
+40% +$2.33K ﹤0.01% 2173
2022
Q2 		$5K Hold
283
– – ﹤0.01% 2433
2022
Q1 		$6K Sell
283
-38
-12% -$769 ﹤0.01% 2387
2021
Q4 		$9K Hold
321
– – ﹤0.01% 2160
2021
Q3 		$7K Buy
321
+38
+13% +$795 ﹤0.01% 2216
2021
Q2 		$5K Hold
283
– – ﹤0.01% 2263
2021
Q1 		$4K Hold
283
– – ﹤0.01% 2215
2020
Q4 		$4K Buy
+283
New +$3.94K ﹤0.01% 2008

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SignatureFD's CRNX Position: Q2 2026 in Review

SignatureFD reduced its Crinetics Pharmaceuticals (CRNX) stake by 24% in Q2 2026, selling an estimated $4.57K and leaving 387 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

SignatureFD first reported a position in CRNX in Q4 2020 and has held it in 23 quarters since. The position peaked at $24.5K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • SignatureFD held 387 shares of Crinetics Pharmaceuticals worth $14.5K as of Q2 2026.
  • SignatureFD sold 123 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $4.57K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2494 holding.
  • SignatureFD first reported a position in Crinetics Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • SignatureFD's Crinetics Pharmaceuticals position peaked at $24.5K in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.